Volume 1, Issue 1 (Feb 2013)                   Res Mol Med (RMM) 2013, 1(1): 1-9 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Valadan R, Rafiei A, Tehrani M, Nejatollahi F. Resistance to HER2-targeted therapy. Res Mol Med (RMM) 2013; 1 (1) :1-9
URL: http://rmm.mazums.ac.ir/article-1-35-en.html
1- Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2- Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran , rafiei1710@gmail.com
3- Recombinant antibody laboratory, Department of Immunology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract:   (7920 Views)


Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug acquire resistance to it and experience tumor recurrence within 1 year. Several molecular and cellular mechanisms underlying the resistance to trastuzumab have been proposed. In this review, first, we provide a brief history leading to production of trastuzumab. Also we consider the cellular and molecular antitumor effects of trastuzumab and then, we discuss the mechanisms underlying trastuzumab resistance in four levels.

Full-Text [PDF 420 kb]   (3157 Downloads)    
Type of Study: Research | Subject: Immunology
Published: 2013/08/11

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Research in Molecular Medicine

Designed & Developed by : Yektaweb